Literature DB >> 8290093

Prevalence of essential tremor: a door-to-door survey in Terrasini, Sicily. Sicilian Neuro-Epidemiologic Study Group.

G Salemi1, G Savettieri, W A Rocca, F Meneghini, V Saporito, L Morgante, A Reggio, F Grigoletto, R Di Perri.   

Abstract

As part of a door-to-door neuroepidemiologic survey, we investigated the frequency and distribution of essential tremor (ET) in a Sicilian municipality. During phase 1, we administered a screening instrument for tremor to 7,653 persons residing in Terrasini (Palermo province). During phase 2, neurologists evaluated those subjects who had screened positive. The diagnoses, based on specified clinical criteria, were reviewed to increase reliability across neurologists. We found 31 subjects affected by ET (17 men, 14 women); 11 patients (35.5%) reported a familial aggregation. The prevalence of ET as of November 1, 1987, was 405.1 per 100,000 for the total population, and 1,074.9 per 100,000 for those 40 years old or older. The prevalence increased with advancing age for both sexes and was slightly but consistently higher in men. Comparison with other studies suggests striking geographic variation, which may reflect genetic differences.

Entities:  

Mesh:

Year:  1994        PMID: 8290093     DOI: 10.1212/wnl.44.1.61

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Population-based case-control study of essential tremor.

Authors:  G Salemi; P Aridon; G Calagna; M Monte; G Savettieri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Clinical characteristics of essential tremor in Mersin, Turkey--a population-based door-to-door study.

Authors:  Okan Dogu; Elan D Louis; Serhan Sevim; Hakan Kaleagasi; Mihriban Aral
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

3.  Low morale is associated with increased risk of mortality in the elderly: a population-based prospective study (NEDICES).

Authors:  Julián Benito-León; Elan D Louis; Jesús Rivera-Navarro; María José Medrano; Saturio Vega; Félix Bermejo-Pareja
Journal:  Age Ageing       Date:  2010-03-17       Impact factor: 10.668

Review 4.  Essential tremor--a neurodegenerative disorder associated with cognitive defects?

Authors:  Félix Bermejo-Pareja
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

5.  Methods and design of the baseline survey of the neurological disorders in Salamanca (NEDISA) cohort: a population-based study in Central-Western Spain.

Authors:  Jesús Cacho; Julián Benito-León; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-01-19       Impact factor: 3.282

6.  Prevalence of essential tremor in Araihazar, Bangladesh: a population-based study.

Authors:  Elan D Louis; Danella Hafeman; Faruque Parvez; Roy N Alcalay; Tariqul Islam; Abu Baker Siddique; Tajul Islam Patwary; Stephanie Melkonian; Maria Argos; Diane Levy; Habibul Ahsan
Journal:  Neuroepidemiology       Date:  2011-01-19       Impact factor: 3.282

7.  A family study on primary blepharospasm.

Authors:  G Defazio; D Martino; M S Aniello; G Masi; G Abbruzzese; S Lamberti; E M Valente; F Brancati; P Livrea; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

8.  Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages.

Authors:  Amir Glik; Magdalena Masarwa; Amin Abuful; Amar Deeb; Rosa Strugatsky; Lindsay A Farrer; Robert P Friedland; Rivka Inzelberg
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

9.  Rate of cognitive decline during the premotor phase of essential tremor: a prospective study.

Authors:  Julián Benito-León; Elan D Louis; Álvaro Sánchez-Ferro; Félix Bermejo-Pareja
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

Review 10.  Alprazolam for essential tremor.

Authors:  Elisa Bruno; Alessandra Nicoletti; Graziella Quattrocchi; Graziella Filippini; Mario Zappia; Carlo Colosimo
Journal:  Cochrane Database Syst Rev       Date:  2015-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.